T1	Measurement 0 21	Body mass index (BMI)
T2	Value 25 41	35 kg/m2 or more
R1	Has_value Arg1:T1 Arg2:T2	
T3	Condition 56 65;80 88	metabolic diseases
T4	Condition 70 88	endocrine diseases
*	OR T3 T4
T5	Condition 104 110	cancer
T6	Drug 120 128	steroids
T7	Drug 132 184	drugs that interfere with the metabolism of estrogen
*	OR T6 T7
T8	Drug 198 215	systemic estrogen
T9	Drug 198 206;217 226	systemic progestin
T10	Drug 231 235	DHEA
T11	Temporal 236 277	in the eight weeks prior to randomization
T12	Scope 198 235	systemic estrogen, progestin, or DHEA
*	OR T9 T8 T10
R2	Has_temporal Arg1:T12 Arg2:T11	
T13	Procedure 287 308	alternative therapies
T14	Drug 312 328	natural products
T15	Condition 338 361	postmenopausal symptoms
T16	Temporal 362 402	in the four weeks prior to randomization
T17	Scope 287 328	alternative therapies or natural products
*	OR T13 T14
R3	AND Arg1:T17 Arg2:T15	
R4	Has_temporal Arg1:T17 Arg2:T16	
T18	Condition 405 422	Palpable fibroids
T19	Condition 426 442	uterine prolapse
*	OR T18 T19
T20	Measurement 444 449	Grade
T21	Value 450 456	2 or 3
R5	Has_value Arg1:T20 Arg2:T21	
T22	Scope 405 442	Palpable fibroids or uterine prolapse
R6	AND Arg1:T22 Arg2:T20	
T23	Condition 459 476	Cigarette smoking
